Turning Point Therapeutics’ Lead Drug Candidate Repotrectinib Increases Effectiveness of KRAS-G12C and MEK Inhibitors in Preclincal KRAS Cancer Models

NEXT STORY
BriaCell Announces Presentation of Clinical and Scientific Findings at AACR Annual Meeting
PREV STORY
Preclinical Data from Assembly Biosciences’ Immuno-Oncology Microbiome Program Featured at AACR’s Virtual Annual Meeting II
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Exalenz Bioscience’s Non-Invasive BreathID® Test to be Evaluated in Two Bristol-Myers Squibb Phase 2b Clinical Trials in Adult Patients with NASH

Studies will use BreathID 13C-methacetin breath test to evaluate patient response to therapy MODI’IN, ...

author_avatar
NASDAQ Market News

OpGen Releases Preliminary Data Demonstrating its Unyvero HPN Panel for Pneumonia Identifies Life-Threatening Bacterial Co-Infections in COVID-19 Patients in Just Five Hours

author_avatar
NASDAQ Market News

electroCore Provides Business Update and Select Financial Guidance

author_avatar
NASDAQ Market News